AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10383502 — intervention group
Group type: COMPARATOR
Intervention: OAC regimen (omeprazole 20 mg b.d., amoxycillin 500 mg t.d.s., clarithromycin 200 mg b.d.)
Number of subjects: 221
Study 10383502 — intervention group
Group type: COMPARATOR
Intervention: LAC regimen (lansoprazole 30 mg b.d., amoxycillin 500 mg t.d.s., clarithromycin 200 mg b.d.)
Number of subjects: 221
Study 10383502 — intervention group
Group type: EXPERIMENTAL
Intervention: RAC regimen (rabeprazole 20 mg b.d., amoxycillin 500 mg t.d.s., clarithromycin 200 mg b.d.)
Number of subjects: 221
Study 8848769 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasteur vaccine (5 micrograms at 0, 1, 2, 6, 18 months)
Number of subjects: 52
Study 8848769 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant vaccine (40 micrograms at 0, 1, 2, 6, 12 months)
Number of subjects: 52
Study 8848769 — intervention group
Group type: COMPARATOR
Intervention: No additional doses
Number of subjects: 52
Study 8848769 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring and administration of additional doses
Number of subjects: 52
Study 1906584 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone (n = 22)
Number of subjects: 47
Study 1906584 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined insulin-glibenclamide therapy (n = 25)
Number of subjects: 47
Study 6341191 — intervention group
Group type: EXPERIMENTAL
Intervention: Urol medication
Number of subjects: 0
Study 6341191 — intervention group
Group type: COMPARATOR
Intervention: Spasmoanalgetic therapy
Number of subjects: 0
Study 31829220 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISMA program in addition to usual care
Number of subjects: 193
Study 31829220 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 193
Study 31829220 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISMA program
Number of subjects: 193
Study 28426542 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage (20-minute aromatherapy foot massage)
Number of subjects: 75
Study 28426542 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation aromatherapy (3-minute inhalation before chemotherapy cycles)
Number of subjects: 75
Study 28426542 — intervention group
Group type: COMPARATOR
Intervention: Control (routine treatment only)
Number of subjects: 75
Study 26707194 — intervention group
Group type: EXPERIMENTAL
Intervention: ADBLOCK system
Number of subjects: 0
Study 25476075 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrobronchoscopic drainage in low CPEF group (at least once a day, frequency increased as needed)
Number of subjects: 102
Study 25476075 — intervention group
Group type: COMPARATOR
Intervention: Fibrobronchoscopic drainage in high CPEF group (when necessary)
Number of subjects: 102
Study 25476075 — intervention group
Group type: EXPERIMENTAL
Intervention: Extubation success without re-intubation within 48 hours
Number of subjects: 102
Study 25476075 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ICU stay duration
Number of subjects: 102
Study 25476075 — intervention group
Group type: COMPARATOR
Intervention: Comparison of re-intubation rates
Number of subjects: 102
Study 25476075 — intervention group
Group type: COMPARATOR
Intervention: Comparison of APACHEII scores
Number of subjects: 102
Study 25476075 — intervention group
Group type: COMPARATOR
Intervention: Comparison of mechanical ventilation time
Number of subjects: 102
Study 22513491 — intervention group
Group type: EXPERIMENTAL
Intervention: School environment intervention with family involvement
Number of subjects: 454
Study 22513491 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 454
Study 21141322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative 5-Fluorouracil (5-FU)
Number of subjects: 30
Study 21141322 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative sub-conjunctival 5-Fluorouracil (5-FU)
Number of subjects: 30
Study 21141322 — intervention group
Group type: COMPARATOR
Intervention: Control group (no 5-FU)
Number of subjects: 30
Study 21141322 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study 17413035 — intervention group
Group type: EXPERIMENTAL
Intervention: 6R‐BH4
Number of subjects: 0
Study 17413035 — intervention group
Group type: EXPERIMENTAL
Intervention: 6S‐BH4
Number of subjects: 0
Study 17413035 — intervention group
Group type: EXPERIMENTAL
Intervention: NH4
Number of subjects: 0
Study 17413035 — intervention group
Group type: COMPARATOR
Intervention: Acetylcholine
Number of subjects: 0
Study 17413035 — intervention group
Group type: COMPARATOR
Intervention: Glyceryl trinitrate
Number of subjects: 0
Study 15848554 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS; 720 mg bid)
Number of subjects: 40
Study 15848554 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF; 1000 mg bid)
Number of subjects: 40
Study 15848554 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EC-MPS and MMF
Number of subjects: 40
Study 12165939 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9807606 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 61
Study 9807606 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 61
Study 7616802 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (1250 IU twice a day subcutaneously for 30 days)
Number of subjects: 20
Study 7616802 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (10 mg per day for 30 days)
Number of subjects: 20
Study 2691480 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanate
Number of subjects: 359
Study 2691480 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole plus gentamicin
Number of subjects: 359
Study 4499921 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 11
Study 4499921 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study 31773199 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel preparation
Number of subjects: 105
Study 31773199 — intervention group
Group type: COMPARATOR
Intervention: No bowel preparation
Number of subjects: 105
Study 31174395 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip strength (HGS) measured using a hydraulic hand dynamometer
Number of subjects: 2045
Study 28089764 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored online coaching with EHR tracking tools (CC)
Number of subjects: 194
Study 28089764 — intervention group
Group type: COMPARATOR
Intervention: EHR tracking tools alone (TO)
Number of subjects: 194
Study 25927183 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized perioperative group: intra‐ and postoperative individualized strategy
Number of subjects: 1012
Study 25927183 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative individualized strategy + postoperative continuous positive airway pressure (CPAP)
Number of subjects: 1012
Study 25927183 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative standard ventilation + postoperative CPAP
Number of subjects: 1012
Study 25927183 — intervention group
Group type: COMPARATOR
Intervention: Intra‐ and postoperative standard strategy (conventional strategy)
Number of subjects: 1012
Study 23723099 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIT) in the fasted state (FAST)
Number of subjects: 16
Study 23723099 — intervention group
Group type: COMPARATOR
Intervention: High-intensity interval training (HIT) in the fed state (FED)
Number of subjects: 16
Study 16879301 — intervention group
Group type: EXPERIMENTAL
Intervention: MBP8298 (500 mg administered intravenously every 6 months)
Number of subjects: 32
Study 16879301 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 32
Study 12556915 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine treatment
Number of subjects: 0
Study 12556915 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 11109308 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (Asmag, Magne B6)
Number of subjects: 0
Study 8924575 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin pretreatment
Number of subjects: 0
Study 8924575 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 1292788 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac perfusion with melphalan
Number of subjects: 117
Study 1292788 — intervention group
Group type: COMPARATOR
Intervention: Femoral perfusion with melphalan
Number of subjects: 117
Study 1292788 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac perfusion
Number of subjects: 117
Study 1292788 — intervention group
Group type: COMPARATOR
Intervention: Femoral perfusion
Number of subjects: 117
Study 6721284 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 0
Study 6721284 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 0
Study 6721284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31793731 — intervention group
Group type: EXPERIMENTAL
Intervention: S. alopecuroides extract (400 mg capsules, once daily)
Number of subjects: 50
Study 31793731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31125614 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline continuous variables from 13 RCTs
Number of subjects: 13
Study 31125614 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline categorical variables from 13 RCTs
Number of subjects: 13
Study 31125614 — intervention group
Group type: COMPARATOR
Intervention: Baseline continuous variables from RCTs with fabricated data
Number of subjects: 13
Study 31125614 — intervention group
Group type: COMPARATOR
Intervention: Baseline categorical variables from RCTs with fabricated data
Number of subjects: 13
Study 31125614 — intervention group
Group type: COMPARATOR
Intervention: Baseline P values from genuine RCTs
Number of subjects: 13
Study 27614318 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubricin (150 μg/mL) eye drops
Number of subjects: 39
Study 27614318 — intervention group
Group type: COMPARATOR
Intervention: Sodium Hyaluronate (HA) 0.18% eye drops
Number of subjects: 39
Study 24746942 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclometasone/formoterol (200 μg/24 μg for children; 400 μg/24 μg for adolescents and adults) via pMDI with AeroChamber Plus™
Number of subjects: 73
Study 24746942 — intervention group
Group type: COMPARATOR
Intervention: Beclometasone/formoterol (400 μg/24 μg) via pMDI with AeroChamber Plus™
Number of subjects: 73
Study 23688206 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic Wave Therapy (AWT(®)), treated once a week for 7 weeks, total of 8 treatments
Number of subjects: 17
Study 23688206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 21400543 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivessel revascularization (MVR)
Number of subjects: 366
Study 21400543 — intervention group
Group type: COMPARATOR
Intervention: Single-vessel revascularization (SVR)
Number of subjects: 366
Study 20074465 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 percent chlorhexidine gel (TG)
Number of subjects: 25
Study 20074465 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG; n=10)
Number of subjects: 25
Study 17453284 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior fundoplication (PF)
Number of subjects: 95
Study 17453284 — intervention group
Group type: COMPARATOR
Intervention: Anterior fundoplication (AF)
Number of subjects: 95
Study 15120931 — intervention group
Group type: EXPERIMENTAL
Intervention: Iseganan 9mg oral rinse, swished/swallowed six times daily for up to 21 days.
Number of subjects: 502
Study 15120931 — intervention group
Group type: COMPARATOR
Intervention: Placebo oral rinse, swished/swallowed six times daily for up to 21 days.
Number of subjects: 502
Study 11584757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin + ferrous sulphate
Number of subjects: 0
Study 11584757 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulphate alone
Number of subjects: 0
Study 9783307 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEpo subcutaneously, 900 U/kg week‐1, 3 times weekly, supplemented with iron and vitamin E
Number of subjects: 107
Study 9783307 — intervention group
Group type: COMPARATOR
Intervention: Control group (116 preterm infants of the same gestational age, admitted to the Neonatal Intensive Care Unit from 1 January 1992 to 31 December 1992)
Number of subjects: 107
Study 8150104 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,000 IU hCG
Number of subjects: 26
Study 8150104 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 26
Study 3152400 — intervention group
Group type: EXPERIMENTAL
Intervention: FM sonography
Number of subjects: 55
Study 3152400 — intervention group
Group type: COMPARATOR
Intervention: AM sonography
Number of subjects: 55
Study 3152400 — intervention group
Group type: COMPARATOR
Intervention: FM sonography and AM sonography
Number of subjects: 55
Study 31162663 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Extraperitoneal (TEP) repair
Number of subjects: 416
Study 31162663 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein repair
Number of subjects: 416
Study 31162663 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TEP and Lichtenstein
Number of subjects: 416
Study 28360244 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP-led clinic for severe SDB
Number of subjects: 0
Study 28360244 — intervention group
Group type: COMPARATOR
Intervention: Physician-led care for severe SDB
Number of subjects: 0
Study 25113527 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz 600 mg nightly for 7 days
Number of subjects: 40
Study 25113527 — intervention group
Group type: COMPARATOR
Intervention: Single dose of a serotonin 2A receptor antagonist
Number of subjects: 40
Study 23143523 — intervention group
Group type: EXPERIMENTAL
Intervention: Long acting injectable (LAI) risperidone
Number of subjects: 446
Study 23143523 — intervention group
Group type: COMPARATOR
Intervention: Oral antipsychotic medications
Number of subjects: 446
Study 21366472 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus administration of furosemide every 12 hours
Number of subjects: 308
Study 21366472 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of furosemide
Number of subjects: 308
Study 21366472 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose furosemide (2.5 times previous oral dose)
Number of subjects: 308
Study 21366472 — intervention group
Group type: COMPARATOR
Intervention: Low-dose furosemide (equivalent to previous oral dose)
Number of subjects: 308
Study 18651551 — intervention group
Group type: EXPERIMENTAL
Intervention: EBPG-based computerised clinical decision support (CDS) system
Number of subjects: 739
Study 18651551 — intervention group
Group type: COMPARATOR
Intervention: No access to EBPG-based computerised clinical decision support (CDS) system
Number of subjects: 739
Study 17046323 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial Fibrillation (AF)
Number of subjects: 55106
Study 17046323 — intervention group
Group type: COMPARATOR
Intervention: Sinus Rhythm (SR)
Number of subjects: 55106
Study 17046323 — intervention group
Group type: COMPARATOR
Intervention: Restrictive filling pattern
Number of subjects: 55106
Study 15130192 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive condition
Number of subjects: 52
Study 15130192 — intervention group
Group type: COMPARATOR
Intervention: Non-competitive condition
Number of subjects: 52
Study 10933269 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive smoking
Number of subjects: 177
Study 10933269 — intervention group
Group type: EXPERIMENTAL
Intervention: Active smoking
Number of subjects: 177
Study 9347277 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (450 to 750 mg)
Number of subjects: 55
Study 9347277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 7504134 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (10.3 ± 6.3 mg/day)
Number of subjects: 48
Study 7504134 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (44.0 ± 11.0 mg/day)
Number of subjects: 48
Study 3550034 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival scaling and root planing under local anesthesia
Number of subjects: 47
Study 3550034 — intervention group
Group type: COMPARATOR
Intervention: Occlusal adjustment
Number of subjects: 47
Study 30462162 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program alone
Number of subjects: 113
Study 30462162 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined-exercise program and nutrition supplement
Number of subjects: 113
Study 30462162 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 113
Study 29326030 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT plus abiraterone acetate (1000 mg) and prednisone (5 mg) once daily
Number of subjects: 1199
Study 29326030 — intervention group
Group type: COMPARATOR
Intervention: ADT plus placebos
Number of subjects: 1199
Study 26730644 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothesis-driven teaching curriculum for pulmonary fellows
Number of subjects: 0
Study 26730644 — intervention group
Group type: COMPARATOR
Intervention: Head-to-toe examination instruction for pulmonary fellows
Number of subjects: 0
Study 24559816 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedative music intervention (soft, instrumental slow music, 60-80 beats per minute, 40 minutes duration, for 6 weeks)
Number of subjects: 60
Study 24559816 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music intervention)
Number of subjects: 60
Study 24559816 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison at week 6
Number of subjects: 60
Study 22516862 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention targeting fathers
Number of subjects: 50
Study 20568023 — intervention group
Group type: EXPERIMENTAL
Intervention: Conivaptan 20 mg IV as a bolus followed by 20 mg IV over 24 h
Number of subjects: 6
Study 20568023 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6
Study 17566112 — intervention group
Group type: EXPERIMENTAL
Intervention: PYY(1-36)
Number of subjects: 24
Study 17566112 — intervention group
Group type: EXPERIMENTAL
Intervention: PYY(3-36)
Number of subjects: 24
Study 17566112 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 24
Study 16032449 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 30
Study 16032449 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 30
Study 12124866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 12124866 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral prasterone
Number of subjects: 191
Study 12124866 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg oral prasterone
Number of subjects: 191
Study 10574618 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-beta1b (8 million international units, subcutaneous)
Number of subjects: 75
Study 10574618 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-beta1a (6 million international units, intramuscular)
Number of subjects: 75
Study 10574618 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 75
Study 10163462 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant micronutrients and trace minerals
Number of subjects: 0
Study 10163462 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 0
Study 1827021 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (7.9 +/- 3.5 mg/day)
Number of subjects: 26
Study 1827021 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (69.2 +/- 43.5 mg/day)
Number of subjects: 26
Study 6927820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergocycle exercise at 55% of VO2 max for 20 minutes
Number of subjects: 8
Study 6927820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergocycle exercise at 70% of VO2 max for 20 minutes
Number of subjects: 8
Study 6927820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergocycle exercise at 85% of VO2 max for 20 minutes
Number of subjects: 8
Study 31757691 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injections (IAIs) 2 mg every 4 weeks for the first 6 months, followed by 2 mg every 8 weeks.
Number of subjects: 31
Study 29574394 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended learning intervention (face-to-face tutorial + online clinical supervisee skills training app)
Number of subjects: 122
Study 28255094 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face motivational interviewing (MI) combined with a self-instruction booklet (W) and follow-up telephone booster sessions (B; MI+W+B)
Number of subjects: 300
Study 28255094 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face cognitive-behavioural therapy (CBT)
Number of subjects: 300
Study 28255094 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcare text messaging (9 months)
Number of subjects: 300
Study 26729009 — intervention group
Group type: EXPERIMENTAL
Intervention: Concise cognitive behavioural therapy and/or pharmacotherapy
Number of subjects: 0
Study 26729009 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 23307554 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 0
Study 23307554 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 0
Study 23307554 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled analyses of total cohort
Number of subjects: 0
Study 21637131 — intervention group
Group type: EXPERIMENTAL
Intervention: MFGM-enriched complementary food (40 g/day)
Number of subjects: 550
Study 21637131 — intervention group
Group type: COMPARATOR
Intervention: Control group (skim milk proteins)
Number of subjects: 550
Study 21637131 — intervention group
Group type: EXPERIMENTAL
Intervention: MFGM-enriched complementary food
Number of subjects: 550
Study 18293165 — intervention group
Group type: EXPERIMENTAL
Intervention: Test lovastatin generic (LVSG)
Number of subjects: 36
Study 18293165 — intervention group
Group type: COMPARATOR
Intervention: Reference (mevinacor 40 MSD)
Number of subjects: 36
Study 16213630 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline QEEG features
Number of subjects: 44
Study 12505243 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment group
Number of subjects: 0